Archives
-
Frizzled5 Cholesterol Sensing Links Wnt to Cancer
2026-10-07
Zheng and colleagues reported that Frizzled5 can bind cholesterol through its extracellular linker, connecting sterol metabolism with receptor maturation, Wnt/β-catenin signaling, and pancreatic ductal adenocarcinoma growth. The study offers a mechanistic framework for understanding how lipid availability can regulate a morphogen receptor, while its therapeutic implications remain dependent on cancer subtype and further validation.
-
Ferrostatin-1: Evidence, Uses, and Limitations
2026-10-06
Ferrostatin-1 (Fer-1) is a research tool used to investigate ferroptosis and oxidative lipid damage. Evidence from a 2024 mouse-ovary study supports a role for ferroptosis in DEHP-associated injury, while also showing why Fer-1 rescue data require cell-, tissue-, and model-specific interpretation.
-
AZ505 and SMYD2 Inhibition: Evidence and Limits
2026-10-06
This source-grounded overview answers five questions about AZ505 as an SMYD2 inhibitor: its biological principle, what potency and selectivity mean, what the cisplatin-induced kidney disease study found, how strong the evidence is, and where the findings should not be extrapolated.
-
CCR7–Notch1 Crosstalk in Mammary Cancer Stemness
2026-10-05
Boyle et al. reported that CCR7 signaling functionally intersects with Notch1 activity in primary MMTV-PyMT mammary tumor cells, linking two regulatory axes associated with cancer stem-like behavior. The study provides preclinical evidence for pathway crosstalk, while its mouse-model design limits direct conclusions about human breast cancer treatment.
-
Berberine, SIRT6-AMPK, and Atrial Fibrillation
2026-10-05
A 2026 International Immunopharmacology study links impaired SIRT6-AMPK signaling with angiotensin II-induced atrial remodeling and shows that berberine suppresses NLRP3 inflammasome activation in a murine model. The findings support a mechanistic connection between metabolic signaling, oxidative stress, inflammation, fibrosis, and atrial fibrillation susceptibility, while remaining preliminary for human treatment.
-
5-Azacytidine in Myeloma: ATR and Synergistic Cytotoxicity
2026-10-04
The 2007 reference study connected 5-azacytidine exposure with ATR-associated DNA double-strand break responses, apoptosis, and enhanced cytotoxicity with doxorubicin or bortezomib in multiple myeloma models. Its main contribution was to broaden the interpretation of a DNA methyltransferase inhibitor from epigenetic modulation alone to a compound capable of producing therapeutically relevant DNA damage in treatment-resistant disease models.
-
Isorhamnetin: From Oocyte Biology to Translation
2026-10-03
A source-grounded analysis of Isorhamnetin as a mechanism-linked research compound in porcine oocyte maturation, with emphasis on PI3K/Akt signaling, oxidative stress, apoptosis, translational evidence boundaries, and strategic study design.
-
Ferrostatin-1 (Fer-1) Experimental Workflows
2026-10-01
Ferrostatin-1 (Fer-1) provides a practical rescue control for distinguishing lipid peroxidation-driven ferroptosis from nonspecific cytotoxicity. This workflow guide covers dose finding, assay design, translational comparisons, and troubleshooting across cancer biology research, neuronal models, and injury-focused experiments.
-
Sulfo-Cy3 NHS Ester for Vascular Labeling
2026-10-01
Sulfo-Cy3 NHS Ester combines water compatibility with efficient amine-reactive labeling, making it useful for soluble proteins, low-solubility targets, endothelial uptake assays, and controlled bioconjugation. This guide translates the AIBP-LRP2 vascular remodeling findings into practical labeling, imaging, quality-control, and troubleshooting workflows.
-
Ferrostatin-1 and Cuproptosis: A Translational Lens
2026-09-30
Ferrostatin-1 (Fer-1) is more than a ferroptosis inhibitor: it is a precision tool for separating lipid peroxidation from other metal-associated death programs. This article examines how Fer-1 can sharpen mechanistic interpretation across cancer biology, neurodegenerative disease models, and emerging parasite research without confusing ferroptosis with cuproptosis.
-
L-Ornithine and the Liver–Brain Axis
2026-09-30
L-Ornithine is more than a urea cycle intermediate: it is a controllable probe for investigating how hepatic nitrogen handling can influence astrocyte metabolism and CNS toxicity. This article translates recent OTC–ornithine–ZBTB7A findings into practical guidance for reproducible metabolic enzyme assays and translational study design.
-
Thymoquinone Protects Against Doxorubicin Cardiotoxicity
2026-09-29
The reference study reports that thymoquinone reduces doxorubicin-induced cardiac injury in mice, linking functional protection with Nrf2/HO-1 activation, improved antioxidant status, and attenuation of ferroptosis-associated changes. Its main contribution is a multimodal in vivo framework that connects cardiac function, redox biomarkers, pathway proteins, and mitochondrial ultrastructure.
-
ZAK Activation at the Collided Ribosome
2026-09-29
The reference study defines how ribosome collisions activate the stress kinase ZAK through RACK1-dependent assembly and SAM-domain dimerization at the collision interface. By combining cryo-electron microscopy, biochemistry, fractionation, and mutational analysis, it distinguishes basal ribosome recruitment from collision-triggered activation and identifies SERBP1 as a negative regulator.
-
Camostat Mesilate: Mechanism Before Endpoint
2026-09-28
Camostat Mesilate is a trypsin-like protease inhibitor best understood through mechanism-separated assays rather than a single endpoint. This guide connects ENaC function, plasmin–TGF-β signaling, hepatic fibrosis, and structure-guided PPI research while clarifying experimental boundaries.
-
Cytochalasin B: Reading Cytotoxicity Assays Carefully
2026-09-28
Cytochalasin B (NSC 107658) is an actin-directed research tool whose effects can reshape how cell-based assay results are interpreted. This article connects its mechanism to practical endpoint selection while carefully distinguishing cytotoxicity, genotoxicity, and cytoskeletal disruption.